Next biotech runner...results imminenet, page-2

Nice to you here blueballs, after your perfect call with mem.

Two other points about the trial. All people receive standard care for 2 weeks first. Those who respond well are the screened out. So only those poor early responders continue on the trial.

A third of these get just the standard care, and they are our drugs benchmark. Given that the good early responders have been removed, it is like that the benchmarks results will be poorer than we have seen in previous trials. However the results we have to date show better than normal results (and this includes 33 percent of subjects on standard care who did not show a good early response).

These suggests we could be heading for a great result. I have a figure in my head but I won't mention it here as I don't want to get people's hopes up too high.

Also subjects have reported less pain, which is also a great result.

Cheers